Guangzhou Innogen Pharmaceutical Group (2591) investor relations material

Executive summary

• H1 2026 revenue rose to RMB78.218m from RMB56.446m as Efsubaglutide Alfa benefited from NRDL access; period loss narrowed to RMB115.460m from RMB122.470m.

• Priorities included expanding T2D access, advancing adult and adolescent obesity trials, overseas registration, and early-stage metabolic-disease programs.

Financial highlights

• Revenue increased to RMB78.218m from RMB56.446m; gross profit rose to RMB56.672m from RMB50.490m.

• Loss for the period was RMB115.460m versus RMB122.470m; basic and diluted loss per share improved to RMB0.25 from RMB0.29.

• Other income and gains reached RMB26.580m, including RMB16.543m in government grants and RMB8.376m in bank interest; selling and distribution expenses rose to RMB62.550m from RMB44.038m.

• R&D expenses fell to RMB85.292m from RMB99.082m, while administrative expenses declined to RMB26.7m from RMB31.6m.

• Other expenses were RMB21.760m, mainly reflecting RMB19.913m in foreign-exchange losses on revaluation of foreign-currency monetary items.

Outlook and guidance

• China Phase III adult obesity and overweight study topline data are expected by year-end 2026, supporting BLA preparation and pre-launch planning.

• Australia Phase II obesity trial data analysis will guide development in Europe, the US and other markets; full trial completion is expected in 2026.

• Commercial priorities include deeper T2D hospital and primary-care coverage, broader sales reach, Hong Kong launch preparations and obesity pre-launch planning, subject to regulatory progress.

• Overseas registration is advancing across selected regions, with launches and sales expected over the next one to two years as registrations progress.

• Future cash needs are expected to focus on candidate development, commercialisation and pipeline expansion.